Journal article
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
BMC cardiovascular disorders, Vol.14(1), pp.121-121
09/20/2014
DOI: 10.1186/1471-2261-14-121
PMCID: PMC4190302
PMID: 25240705
Abstract
Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.
The COMBO studies, part of the Phase 3 ODYSSEY clinical trial program, are designed to evaluate the efficacy and safety of alirocumab as add-on therapy to stable, maximally tolerated daily statin, with or without other lipid-lowering therapy (LLT), in a planned 966 patients with hypercholesterolemia at high cardiovascular risk. COMBO I ( http://clinicaltrials.gov/show/NCT01644175) is placebo-controlled, with a double-blind treatment period of 52 weeks, and 306 planned patients who may receive other LLTs in addition to statin therapy. COMBO II ( http://clinicaltrials.gov/show/NCT01644188) has a double-blind treatment period of 104 weeks, comparing alirocumab with ezetimibe in 660 planned patients receiving statin therapy (but no other LLTs). The primary efficacy endpoint is the difference between treatment arms in percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to week 24. Both studies utilized a starting dose of alirocumab 75 mg every 2 weeks (Q2W; administered as 1 mL solution via auto-injector). Patients with LDL-C levels ≥70 mg/dL after 8 weeks of treatment were up-titrated in a blinded manner at week 12 to alirocumab 150 mg Q2W (also 1 mL auto-injector).
In conclusion, the COMBO studies will provide information on the long-term efficacy and safety of alirocumab in high-risk patients when administered in addition to maximally tolerated statin therapy, with a flexible dosing strategy which allows for individualized therapy based on the degree of LDL-C lowering needed to achieve the desired treatment response.
NCT01644175 ( NCT01644175).
NCT01644188 ( NCT01644188).
Details
- Title: Subtitle
- Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
- Creators
- Helen M Colhoun - University of Dundee, Dundee, Scotland DD2 4BF, UK. h.colhoun@dundee.ac.ukJennifer G RobinsonMichel FarnierBertrand CariouDirk BlomDean J KereiakesChristelle LorenzatoRobert PordyUmesh Chaudhari
- Resource Type
- Journal article
- Publication Details
- BMC cardiovascular disorders, Vol.14(1), pp.121-121
- Publisher
- England
- DOI
- 10.1186/1471-2261-14-121
- PMID
- 25240705
- PMCID
- PMC4190302
- ISSN
- 1471-2261
- eISSN
- 1471-2261
- Language
- English
- Date published
- 09/20/2014
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995174402771
Metrics
14 Record Views